Skip to main navigation Skip to search Skip to main content

24-NHL-38-AT-PMC (ALLO-501A-202): A Randomized, Open-Label Study Evaluating The Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA 3)

Grants and Contracts Details

StatusActive
Effective start/end date8/9/24 → 8/9/27

Funding

  • Allogene Therapeutics Incorporated: $67,580.00